Open Site Navigation

Amixicile: A Concept Therapeutic for Treatment of Chronic Anaerobic Infections

Updated: May 2

Source: British Journal of Gastroenterology (2019)


Amixicile is a selective anaerobic microbial therapeutic in development to treat chronic infections caused by anaerobic bacteria including periodontal disease and is designed for use for long term management of colitis caused by Clostrioides difficile.


Amixicile-_A_Concept_Therapeutic_for_Treatment_of_Chronic_Anaerobic_Infections
.pdf
Download PDF • 422KB

©2022 by Direct Diagnostics LLC. Direct Diagnostics is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meets the requirements to perform high complexity tests. CLIA Registration 45D2190910. 

Direct Diagnostics is certified under the College of American Pathologists (CAP), CAP Accreditation #9088531

Website by Redwood Designs.

  • Instagram
  • LinkedIn | Direct Dx
  • Facebook
  • YouTube